Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· July 23, 2026

Multiverse Computing Unveils Breakthrough: All CompactifAI Models Now Run on Intel Xeon 6 Processors

View original at finance.yahoo.com
Multiverse Computing Unveils Breakthrough: All CompactifAI Models Now Run on Intel Xeon 6 Processors Multiverse Computing Advancement delivers significant performance improvements, energy savings, and reductions in memory footprint while preserving accuracy SAN SEBASTIÁN, Spain, July 23, 2026 (GLOBE NEWSWIRE) -- Multiv…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The CompactifAI-compressed model retained strong accuracy relative to the uncompressed baseline, with only minor variations observed on standard benchmarks.

    60% confidence
  • At one concurrent user, the compressed model reduced processing time from 5,056.34 seconds to 2,598.22 seconds, a 48.6% latency reduction.

    60% confidence
  • The CompactifAI-compressed Llama 3.3 70B model delivered an output throughput of 3.86 tokens/second and total token throughput of 7.81 tokens/second, improvements of 93.6% and 94.1% over the uncompressed baseline.

    60% confidence
  • ITL, TPOT, and TTFT metrics showed substantial reductions: ITL mean fell 48.9%, TPOT mean fell 48.3%, and TTFT mean fell 46.6%.

    60% confidence
  • At the highest concurrency level tested (256 concurrent users), throughput increased by 107.0% and latency decreased by 51.7%.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com